

Confirmed Speakers

EFMC Award Lectures

PROUS INSTITUTE - OVERTON AND MEYER AWARD FOR NEW TECHNOLOGIES IN DRUG DISCOVERY
AL003 - How PROTACs Work: Molecular Recognition and Design Principles

Prof. Alessio CIULLI
(UNIVERSITY OF DUNDEE, Dundee, United Kingdom)

NAUTA PHARMACOCHEMISTRY AWARD FOR MEDICINAL CHEMISTRY AND CHEMICAL BIOLOGY
AL001 - Pseudo Natural Products – Chemical Evolution of Natural Product Structure

Prof. Herbert WALDMANN
(MAX PLANCK INSTITUTE OF MOLECULAR PHYSIOLOGY, Dortmund, Germany)

UCB EHRLICH AWARD FOR EXCELLENCE IN MEDICINAL CHEMISTRY
AL002 - Small Molecule Drugs and where to find them - Approaches to Hit Generation and Lead Optimisation

Prof. Mike WARING
(NEWCASTLE UNIVERSITY, Newcastle upon Tyne, United Kingdom)

Prize Lectures

IUPAC-RICHTER PRIZE 2022
PR004 - Drug Discovery in Academia: A Drug For Glioblastoma Multiforme

Prof. Michael E. JUNG
(UCLA CHEMISTRY & BIOCHEMISTRY, Los Angeles, United States)

EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN INDUSTRY
PR002 - Chemical Biology Strategies Applied to Phenotypic Screening and Targeted Protein Degradation Discovery Programs

Dr Marie-Helene LARRAUFIE
(ALMIRALL, Barcelona, Spain)

GALAPAGOS AWARD LECTURE (Award-winning Team: Bioversys/University of Lille/GSK)
LE025 - Rejuvenating Ethionamide for Treatment of Tuberculosis - TRICKy, but Possible

Dr Modesto REMUINAN
(GSK, Tres Cantos (Madrid), Spain)

KLAUS GROHE PRIZE 2022
Discovery of a Druggable Copper-signaling Pathway that Drives Cell Plasticity and Inflammation

Dr Raphaël RODRIGUEZ
(INSTITUT CURIE, Paris, France)

EFMC PRIZE FOR A YOUNG MEDICINAL CHEMIST OR CHEMICAL BIOLOGIST IN ACADEMIA
PR003 - Chemical Biology Tools for Enlightening Drug Discovery

Prof. Olalla VÁZQUEZ
(PHILIPPS-UNIVERSITÄT MARBURG, Marburg, Germany)

Plenary Speakers

PL001 - Boosting « Chance and Necessity » with Experience and Molecular Creativity

Prof. Benoit DEPRez
(INSTITUT PASTEUR DE LILLE, Lille, France)

PL002 - The Shape and Modification of RNA in Health and Disease

Prof. Eric Miska
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

PL003 - Necessity is the Mother of Invention: Natural Products and the Chemistry They Inspire

Confirmed Speakers

Prof. Sarah E. REISMAN
(CALIFORNIA INSTITUTE OF TECHNOLOGY, Pasadena, United States)

PL004 - Drivers of Innovation in Drug Discovery

Prof. Outi VAARALA
(ORION CORPORATION, Espoo, Finland)

Invited Speakers

LE092 - De Novo Cyclic Peptides as Chemical Tools to Explore Epigenetic Regulation

 (SANOFI-AVENTIS DEUTSCHLAND GMBH)

Dr Louise WALPORT (THE FRANCIS CRICK INSTITUTE, London, United Kingdom)

LE085 - Addressing Current Challenges in Antiviral Therapies Against Emerging RNA Viruses

Dr Karine ALVAREZ
(AIX-MARSEILLE UNIVERSITY, Marseille, France)

LE029 - Fragment-Based Approaches to Stabilize Protein-Protein Interactions

Prof. Michelle ARKIN
(UNIVERSITY OF CALIFORNIA, San Francisco, CA, United States)

LE086 - Embrace Complexity: in Silico Polypharmacological Profiling to Repurpose Medicines and Design New Drugs

Dr Andrea BECCARI
(DOMPÉ PHARMA, L'Aquila, Italy)

LE020 - Inhibiting the MYC Oncogene through Cell Active Max-E47 (ME-47)

Dr Amy BITTNER MCCracken
(MSD, New Jersey, United States)

LE033 - The Global Antibiotic R&D Partnership: Helping to Advance the Discovery & Development of New Treatments for Bacterial Infections

Dr Benjamin BLASCO
(THE GLOBAL ANTIBIOTIC RESEARCH & DEVELOPMENT PARTNERSHIP (GARDP) , Geneva, Switzerland)

LE064 - Molecular Vending Machines for the On-Demand Synthesis of Drug-Like Molecules

Prof. Jeffrey BODE
(ETH ZURICH, Zürich, Switzerland)

LE081 - A Novel Fragment-Based Ligand Design Tool : Application to Kinase Research

Prof. Pascal BONNET
(UNIVERSITY OF ORLÉANS, Orléans, France)

LE022 - A DNA Barcode with Enhanced Chemical Stability for DNA-encoded Library Design

Dr Andreas BRUNSCHWEIGER
(TU DORTMUND, Dortmund, Germany)

LE101 - Medicinal Chemistry in the Development of Molecular Imaging Probes Targeting Prostate-Specific Membrane Antigen

Prof. Youngjoo BYUN
(KOREA UNIVERSITY, Sejong, Korea, South)

LE074 - Fundamental Basis for SMN2 Specific Splicing Correction by Small Molecules and Bulge Repair Mechanism

Dr Sébastien CAMPAGNE
(INSERM BORDEAUX, BORDEAUX, France)

LE065 - Photocatalysis in Drug Discovery

Confirmed Speakers

Dr Lisa CANDISH
(BAYER, Wuppertal, Germany)

LE050 - A Perspective on AI and Automation for the Medicinal Chemistry Lab *Virtual Presentation*

Prof. Connor COLEY
(MIT, Cambridge, United States)

LE035 - Discovery and Preclinical Development of ANT3310, a Broad-Spectrum β -Lactamase Inhibitor which Potentiates Meropenem Against Carbapenem-Resistant Bacteria

Dr David DAVIES
(ANTABIO SAS, Labège, France)

LE051 - The Power and Pitfalls of Machine Learning in Early Stage Drug Discovery

Prof. Charlotte DEANE
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

LE034 - Novel Tetrazole Inhibitor of Mycobacterium Tuberculosis Tryptophan Synthase

Dr Lourdes ENCINAS
(GLAXOSMITHKLINE, Madrid, Spain)

EFMC-YMCS Prize 2021

LE016 - A Mating Mechanism to Generate Diversity for the Darwinian Selection of DNA-encoded Synthetic Molecules

Mr Lluc FARRERA SOLER
(UNIVERSITY OF GENEVA, Geneva, Switzerland)

LE073 - Targeting RNA with Small Molecules, A New Therapeutic Strategy

Dr Yann FORICHER
(SANOFI, Vitry-sur-Seine, France)

LE019 - Discovery of KB-0742, a Potent, Selective, Orally Bioavailable Small Molecule Inhibitor of CDK9/Cyclin T1 for MYC-Dependent Cancers

Dr David FREEMAN
(KRONOS BIO, INC., Massachusetts, United States)

LE042 - Leveraging Biomolecular Condensates for Drug Discovery

Dr Marta FRIGOLE-VIVAS
(DEWPOINT THERAPEUTICS GMBH, Dresden, Germany)

LE072 - Enabling Technologies for Revealing Druggable Paths in RNA Biology

Dr Amanda GARNER
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

LE009 - New Synthetic Chemistry to Probe the Biology of Modified Nucleic Acids

Prof. Matthew GAUNT
(UNIVERSITY OF CAMBRIDGE, Cambridge, United Kingdom)

LE047 - Discovery of Covalent Protein Kinase Inhibitors Targeting Cysteines in the Hinge Region

Prof. Matthias GEHRINGER
(UNIVERSITY OF TUEBINGEN, Tuebingen, Germany)

LE084 - Searching for Drugs against Pandemic Viruses

Dr Carmen GIL
(CENTRO DE INVESTIGACIONES BIOLÓGICAS (CSIC), Madrid, Spain)

LE049 - Driving Lead Optimization with BRADSHAW

Dr Darren GREEN
(GSK, Stevenage, United Kingdom)

Confirmed Speakers

LE046 - Covalent Fragment Approaches in Drug Discovery

Prof. György KESERU
(HUNGARIAN ACADEMY OF SCIENCES, Budapest, Hungary)

LE017 - Chemical Probe Discovery for Recalcitrant Targets *Virtual Presentation*

Prof. Angela KOEHLER
(MIT KOCH INSTITUTE FOR INTEGRATIVE CANCER RESEARCH, Cambridge, United States)

LE097 - Selective Butyrylcholinesterase Inhibitors for Alleviating Symptoms of Dementia

Dr Urban KOSAK
(UNIVERSITY OF LJUBLJANA, Ljubljana, Slovenia)

LE045 - Inhibiting KRAS: Strategies, Structures, and Lessons Learned in the Invention of Sotorasib

Dr Brian LANMAN
(AMGEN, Thousand Oaks, CA, United States)

LE001 - Strategies to Discover Molecular Glue Degradable at Scale

Dr Cristina MAYOR-RUIZ
(IRB BARCELONA, Barcelona, Spain)

LE010 - Tritiation of Pharmaceuticals Via Late Stage C-H Functionalization

Dr Dieter MURI
(ROCHE - PHARMA RESEARCH AND EARLY DEVELOPMENT (PRED), Basel, Switzerland)

LE080 - The Phosphatase Family: a Widely Neglected Target Space for Small-Molecule Drug Discovery

Dr Gerhard MÜLLER
(ANAVO THERAPEUTICS, Leiden, The Netherlands)

LE061 - The discovery of the Clinical Candidate AZD0284, a Orally Bioavailable Inverse Agonist of RORγ for the Treatment of Psoriasis

Dr Frank NARJES
(ASTRAZENECA, Gothenburg, Sweden)

LE013 - Disrupting hDot1L and MLL Oncofusion Protein Interactions as a Novel Therapeutic Strategy

Prof. Zaneta NIKOLOVSKA-COLESKA
(UNIVERSITY OF MICHIGAN, Ann Arbor, United States)

LE100 - Evaluation of Cancer Immunity and Development of Novel Radiolabeling Method with Astatin-211 *Virtual Presentation*

Dr Mikako OGAWA
(HOKKAIDO UNIVERSITY, Sapporo, Japan)

LE078 - Opportunity and Challenge of Artificial Intelligence (AI) in Drug Delivery *Virtual Presentation*

Prof. Defang OUYANG
(MACAU UNIVERSITY, Macau, China)

LE057 - Tumor Activated Therapy

Prof. Sebastien PAPOT
(UNIVERSITY OF POITIERS, Poitiers, France)

LE091 - Chemical Probes and How to Find Them

Dr Alex PAUTSCH
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany)

LE062 - Macrolide Inspired Macrocycles as Effective Disruptors of the IL-17A/IL-17RA Interaction

Dr Dijana PESIC
(SELVITA, Zagreb, Croatia)

Confirmed Speakers

LE014 - New Opportunities for Studying the Function of the Nucleosome Remodeling Factor, NURF, Through Inhibition and Degradation

Prof. William POMERANTZ
(UNIVERSITY OF MINNESOTA, Minneapolis, United States)

LE093 - Chemical Probes for Targets in Lipid Signalling

Prof. Eugen PROSCHAK
(GOETHE UNIVERSITY OF FRANKFURT, Frankfurt/Main, Germany)

LE038 - EDELRIE Keychemical Space™ and GPCR : Identification of Allosteric Binders by AS-MS

Dr Renaud PRUDENT
(EDELRIE, Lyon, France)

LE060 - Tipping the Balance: MALT1 Inhibitors with Paradoxical Effects on the Immune System

Dr Jean QUANCARD
(NOVARTIS, Basel, Switzerland)

LE018 - Transcription Factors as Drug-Discovery Targets

Prof. Fraydoon RASTINEJAD
(UNIVERSITY OF OXFORD, Oxford, United Kingdom)

LE058 - Investigating and Controlling mRNAs Via Chemo-enzymatic Modification

Prof. Andrea RENTMEISTER
(UNIVERSITY OF MÜNSTER, Münster, Germany)

LE011 - Late-Stage Functionalizations

Prof. Tobias RITTER
(MAX-PLANCK-INSTITUT FÜR KOHLENFORSCHUNG, Mülheim, Germany)

LE056 - Chemically-Triggered Payload Release in-vivo

Dr Marc ROBILLARD
(TAGWORKS PHARMACEUTICALS, Eindhoven, The Netherlands)

LE005 - Big Data Analyses for the Discovery of Lead Structures from Nature

Prof. Judith ROLLINGER
(UNIVERSITY OF VIENNA, Vienna, Austria)

LE006 - Design of Naturally Inspired Anti-Cancer Compounds that Modulate Cholesterol Homeostasis

Dr Fanny ROUSSE
(ICSN - CNRS, Gif sur Yvette, France)

LE021 - Innovating DNA-encoded Chemical Library Technology for Better Ligand Discovery

Dr Jörg SCHEUERMANN
(ETH ZÜRICH, Zürich, Switzerland)

LE099 - Radiotheragnostics from Bench-to-Bedside *Virtual Presentation*

Prof. Roger SCHIBLI
(ETH ZÜRICH, Zürich, Switzerland)

LE037 - Adapting the Affinity MS Technology to GPCR Ligand Discovery *Virtual Presentation*

Prof. Wenqing SHUI
(SHANGHAITECH UNIVERSITY, Shanghai, China)

LE041 - Targeting Protein-Protein Interactions of Receptor Complexes

Prof. Kristian STROMGAARD
(UNIVERSITY OF COPENHAGEN, Copenhagen, Denmark)

LE002 - Haven't Got a Glue: Protein Surface Variation for the Design of Molecular Glue Degraders

Confirmed Speakers

Dr Nicolas THOMÄ
(FRIEDRICH MIESCHER INSTITUTE FOR BIOMEDICAL RESEARCH, Basel, Switzerland)

LE068 - Formulation Strategies for Compounds with Challenging Physicochemical Properties

Prof. Guy VAN DEN MOOTER
(KULEUVEN, Leuven, Belgium)

LE039 - High Throughput Affinity Screening for Rapid Hit Discovery and Prosecuting Intractable Targets

Dr Jarrod WALSH
(ASTRAZENECA, Macclesfield, United Kingdom)

LE076 - Uncertainty Quantification: Considering the Reliability of Artificial Intelligence in Drug Design *Virtual Presentation*

Dr Dingyan WANG
(SHANGHAI INSTITUTE OF MATERIA MEDICA, Shanghai, China)

LE095 - Beyond Amyloid and Tau: Exploring Alternative Therapeutic Targets Using an Integrative Approach

Prof. Daniel WATTERSON
(NORTHWESTERN UNIVERSITY, Chicago, United States)

LE077 - Innovative Therapeutic Target Discovery based on OMIC Technology and Machine Learning *Virtual Presentation*

Prof. Feng ZHU
(ZHEJIANG UNIVERSITY, Hangzhou, China)

Oral Communication

LE012 - Chemical Modification of Wild-type Proteins

Dr Bauke ALBADA
(WUR, Wageningen, The Netherlands)

LE030 - Development of Bisubstrate Inhibitors to Tackle Epigenetics

Dr Paola B. ARIMONDO
(INSTITUT PASTEUR - CNRS, Paris, France)

LE066 - Visible-light Photocatalysis: a Powerful Tool in the Pursuit of New Pharmaceuticals

Dr Giulia BERGONZINI
(ASTRAZENECA, Gothenburg, Sweden)

LE096 - Discovery of Selective NKCC1 Inhibitors for the Treatment of Core Symptoms in Autism, Down Syndrome, and Brain Disorders with Defective NKCC1/KCC2 Ratio

Dr Marco BORGOGNO
(IAMA THERAPEUTICS SRL, Genoa, Italy)

LE036 - Discovery of Pseudomonas Aeruginosa Elastase LasB Inhibitors by in Situ Click Chemistry

Dr Virgyl CAMBERLEIN
(HIPS - HELMHOLTZ-INSTITUT FÜR PHARMAZEUTISCHE FORSCHUNG SAARLAND, Saarbrücken, Germany)

LE088 - Discovery of Clinical Candidate CHF-6366: a Super-soft Heterobifunctional Muscarinic Antagonist and α 2-adrenoceptor Agonist (MABA) for the Inhaled Treatment of Respiratory Diseases

Dr Laura CARZANIGA
(CHIESI FARMACEUTICI SPA, PARMA, Italy)

LE008 - Tuning the Reactivity of the Natural Product Andrographolide: Towards Targeted Covalent Inhibitors for the Treatment of Inflammation

Confirmed Speakers

Prof. Christina CHAI
(NATIONAL UNIVERSITY OF SINGAPORE, Singapore, Singapore)

LE040 - Accelerating Drug Discovery with the Integration of Affinity Selection Mass Spectrometry (ALIS)

Mr Bryan CHOI
(RELAY THERAPEUTICS, Cambridge, United States)

LE094 - First Selective Nanomolar Inhibitors of ERAP2 for Modulation of the Antigen Presentation

Prof. Rebecca DEPREZ-POULAIN
(INSERM - UNIVERSITÉ DE LILLE / INSTITUT PASTEUR OF LILLE, Lille, France)

LE032 - Molecular Glues for the 14-3-3 Interactome

Dr Richard DOVESTON
(UNIVERSITY OF LEICESTER, Leicester, United Kingdom)

LE007 - Reduce to the Max: Functionally Optimized Natural Products via Chemical Synthesis

Prof. Karl GADEMANN
(UNIVERSITY OF ZÜRICH, Zürich, Switzerland)

LE079 - In Silico Prediction of Brain Penetration - High Accuracy Achieved

Dr Herve GENESTE
(ABBVIE, Ludwigshafen, Germany)

LE063 - NR2F6 Antagonists: in Vitro Pharmacology and Preclinical Data of a Potential Next Generation Immuno-oncology Therapy

Dr Francesco GRECO
(TES PHARMA SRL, Perugia, Italy)

LE090 - Structure-Guided Design of Foldamer-Based Inhibitors of Protein-Protein Interactions

Dr Gilles GUICHARD
(UNIVERSITY OF BORDEAUX, CBMN, Bordeaux, France)

LE004 - Discovery And Profiling of AZ'6421: an Oral ER α -Protac with an in vitro-in vivo Disconnect

Dr Thomas HAYHOW
(ASTRAZENECA, Cambridge, United Kingdom)

LE070 - Optimization of TEAD P-Site Binding Fragment Hit into In Vivo Active Lead MSC-4106

Dr Timo HEINRICH
(MERCK, DARMSTADT, Germany)

LE024 - Photoactivated Covalent Capture of DNA-encoded Fragments to Identify Ligands for Challenging Targets

Prof. Roderick HUBBARD
(VERNALIS, Cambridge, United Kingdom)

LE089 - Discovery of JNJ-1245, a Novel and Potent Fluoroallylamide Mcl-1 Inhibitor for the Treatment of Hematologic Malignancies

Dr Soufyan JERHAOUI
(JANSSEN PHARMACEUTICA NV, Beerse, Belgium)

LE031 - Identification and Structure-activity Relationship Profiling of Positive Allosteric Modulators Targeting Muscarinic Acetylcholine Receptors

Dr Manuela JORG
(MONASH UNIVERSITY, Parkville, Australia)

LE102 - Development of First PET Tracers for the Imaging of CD73 Expression in Triple-negative Breast Cancer

Confirmed Speakers

Dr Anna JUNKER
(EUROPEAN INSTITUTE FOR MOLECULAR IMAGING, Muenster, Germany)

LE069 - Dual Inhibition of P53-MDM2/4 Interactions With Spiropyrazoline Oxindoles

Ms Elizabeth A. LOPES
(UNIVERSITY OF LISBON, Lisboa, Portugal)

LE023 - Exploiting DNA-encoded Library Technology for the Discovery of Novel Antibody Recruiting Molecules Against LOX-1

Ms Katherine MACFARLANE
(UNIVERSITY OF STRATHCLYDE, London, United Kingdom)

LE003 - Antibody-Protac Conjugates: an Approach for Targeted Selective BRD4 Degradation in HER2+ Phenotypes

Dr Maria MANEIRO
(UNIVERSIDADE DE SANTIAGO DE COMPOSTELA, Santiago de Compostela, Spain)

LE098 - Modulation of TDP-43-pathway by Brain Penetrant Protein Kinase Inhibitors, a New Hope for ALS and Related Disorders

Prof. Ana MARTINEZ
(CENTRO DE INVESTIGACIONES BIOLÓGICAS-CSIC, Madrid, Spain)

LE083 - Mining the Leishmania Kinome

Dr Exequiel PORTA
(DURHAM UNIVERSITY, Durham, United Kingdom)

LE015 - New Generation of EZH2 Inhibitors for Cancer Therapy: A Computer-Aided Drug Design Approach in Epigenetics

Dr Filipa RAMILO-GOMES
(UNIVERSITY OF LISBON, Lisboa, Portugal)

LE087 - Human Dihydroorotate Dehydrogenase Inhibitor MEDS443: a Magic Bullet Against Coronaviruses

Dr Stefano SAINAS
(UNIVERSITY OF TORINO, Torino, Italy)

LE052 - Using AI to Derive Valuable Insights from Drug Discovery Data

Dr Matthew SEGALL
(OPTIBRIUM, Cambridge, United Kingdom)

LE075 - Bis-3-chloropiperidines Targeting TAR RNA as a Novel Strategy to Impair the HIV-1 Nucleocapsid Protein

Dr Alice SOSIC
(UNIVERSITY OF PADOVA, Padova, Italy)

LE044 - Interrogating Lactate Dehydrogenases Oligomeric Interfaces Using (Stapled) Peptides And Small Molecules

Dr Léopold THABAULT
(INSTITUTE OF CANCER RESEARCH, London, United Kingdom)

LE059 - Fast Detection and Imaging of Hydrogen Peroxide with New Borinic Probes

Dr Boris VAUZEILLES
(INSTITUT DE CHIMIE DES SUBSTANCES NATURELLES, Gif-sur-Yvette, France)

LE071 - A New Dual Mode of Action to Treat Pain - From Scratch to Pre-Clinical Candidate

Dr Anita WEGERT
(SYMERES, Nijmegen, The Netherlands)

LE067 - Iridium-catalyzed C-H Activation Methods for Late-stage Functionalization of Pharmaceuticals

Confirmed Speakers

Dr Erik WEIS
(ASTRAZENECA, Mölndal, Sweden)

LE082 - Protein Phosphatase 2A, a Druggable Tumor Suppressor for Cancer Therapy

Prof. Jukka WESTERMARCK
(UNIVERSITY OF TURKU, Turku, Finland)

LE048 - Discovery of Novel Covalent, EGFR WT Sparing, HER2 Selective Inhibitors for the Treatment of Her2 Exon 20 Insertion Driven Tumours

Dr Birgit WILDING
(BOEHRINGER INGELHEIM, Vienna, Austria)

First Time Disclosures

LE055 - Discovery and Optimisation of Potent, Slow-dissociating Inhaled PI4KB Inhibitors

Dr Sophie BERTRAND
(GSK, Stevenage, United Kingdom)

LE028 - Discovery of AZD5462, an Oral Agonist of the Relaxin Family Peptide Receptor 1 (RXFP1) for the Treatment of Cardiorenal Disease

Dr Kenneth GRANBERG
(ASTRAZENECA, Mölndal, Sweden)

LE054 - First Disclosure of Cannabinoid Receptor Type 2 Agonist Rg7774 – An Innovative Oral Treatment for Diabetic Retinopathy

Dr Uwe GRETHNER
(F. HOFFMANN-LA ROCHE, Basel, Switzerland)

LE027 - Discovery of BI 456906, a Novel Long-acting GCG/GLP-1 Receptor Dual Agonist for the Treatment of Patients With Obesity

Dr Peter HAEBEL
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach Riss, Germany)

Session Chair

Dr Pilar MANZANO-CHINCHON
(GLAXOSMITHKLINE, Tres Cantos (Madrid), Spain)

Session Chair

Dr Leena OTSOMAA
(ORION PHARMA, Espoo, Finland)

LE053 - mPGES1 Inhibitors: First Time Disclosure of Clinical Candidate BI01029539 / GS-248

Dr Roland PFAU
(BOEHRINGER INGELHEIM PHARMA GMBH&CO. KG, Ingelheim am Rhein, Germany)

LE026 - First-time Disclosure of M1069, a Highly Selective Dual Inhibitor of Adenosine A_{2a}/A_{2b} Receptors With Improved Therapeutic Activity Compared to A_{2a} Receptor Selective Antagonists

Dr Kai SCHIEMANN
(MERCK HEALTHCARE KGAA, Darmstadt, Germany)

LE103 - Discovery of a Selective Oral CCR4 Antagonist RPT193 for Treatment of Atopic Dermatitis and other Allergic Disorders

Dr Mikhail ZIBINSKY
(RAPT THERAPEUTICS, INC., South San Francisco, United States)

EFMC Prizes for Young Medicinal Chemist or Chemical Biologist in Academia and in Industry Ceremony & Lectures